Fax: (617) 789-2959
Version of Record online: 8 JAN 2004
Copyright © 2004 American Cancer Society
Volume 100, Issue 4, pages 859–868, 15 February 2004
How to Cite
Hesketh, P. J., Arena, F., Patel, D., Austin, M., D'Avirro, P., Rossi, G., Colowick, A. and Schwartzberg, L. (2004), A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies. Cancer, 100: 859–868. doi: 10.1002/cncr.11954
Performed on behalf of the Darbepoetin Alfa 20010102 Study Group. The authors thank the study coordinators and patients at each of the participating centers. Janis Schaap, M.A., assisted in the writing of the article.
Additional members of the Darbepoetin Alfa 20010102 Study Group include the following: Luigi F. Bertoli, M.D. (Clinical Research Consultants, Inc., Hoover, Alabama); John T. Cole, M.D. (Ochsner Clinic Foundation, New Orleans, Louisiana); George Demetri, M.D. (Dana-Farber Cancer Institute, Boston, Massachusetts); Emmanuel Dessypris, M.D. (Hunter Holmes McGuire Department of Veterans Affairs Medical Center, Richmond, Virginia); Tracy Dobbs, M.D. (Baptist Hospital of East Tennessee, Knoxville, Tennessee); Peter Eisenberg, M.D. (California Cancer Care, Inc., Greenbrae, California); Roger Fleischman, M.D., Ph.D. (University of Kentucky Veterans Affairs Medical Center, Lexington, Kentucky); James Hall, M.D. (Blumenthal Cancer Center/Carolinas Medical Center, Charlotte, North Carolina); Phillip C. Hoffman, M.D. (University of Chicago, Chicago, Illinois); Damian A. Laber, M.D. (James Graham Brown Cancer Center, University of Louisville, Louisville, Kentucky); John Leonard, M.D. (New York Presbyterian Hospital, New York, New York); Eric P. Lester, M.D. (Oncology Care Associates, St. Joseph, Michigan); Spence McCachren, M.D. (Thompson Cancer Survival Center, Knoxville, Tennessee); Scott McMeekin, M.D. (The University of Oklahoma, Oklahoma City, Oklahoma); Luis Meza, M.D. (South West Oncology Associates, Lafayette, Louisiana); David Scott Miller, M.D. (University of Texas Southwestern Medical Center, Dallas, Texas); Sucha Nand, M.D. (Loyola University Medical Center, Cardinal Bernardin Cancer Center, Maywood, Illinois); Ira Oliff, M.D. (Midwest Cancer Research Group, Skokie, Illinois); Warren Paroly (Sharp Oncology Research, San Diego, California); Larry Pawl, M.D. (Spectrum Health, Grand Rapids, Michigan); Alejandra Perez, M.D. (Offices of Gabriel Domenech, M.D., Plantation, Florida); Harry Raftopoulos, M.D. (Columbia Presbyterian Medical Center, New York, New York); James Rigas, M.D. (Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire); Kendrith Rowland, M.D. (Carle Cancer Center Research Department, Urbana, Illinois); Daniel C. Scullin, Jr., M.D. (Consultants in Blood Disorders and Cancer, Louisville, Kentucky); Haluk Tezcan, M.D. (North Idaho Cancer Center, Coeur D'Alene, Idaho); John Waples, M.D. (Comprehensive Cancer Institute, Huntsville, Alabama); John Ward, M.D. (Huntsman Cancer Institute, Salt Lake City, Utah); Lorrin K. Yee, M.D. (North West Medical Specialties, Tacoma, Washington).
- Issue online: 3 FEB 2004
- Version of Record online: 8 JAN 2004
- Manuscript Accepted: 6 NOV 2003
- Manuscript Revised: 5 NOV 2003
- Manuscript Received: 28 AUG 2003
- Amgen Inc. (Thousand Oaks, CA)
- 2Recombinant human erythropoietin (rHuEPO) for the treatment of the anemia of cancer. In: MurphyMJJr., editor. Blood cell growth factors: their present and future use in hematology and oncology. Proceedings of the Beijing Symposium. Dayton: AlphaMed Press, 1991: 121–142., , , .
- 15The science of erythropoiesis: quantification of factors influencing response by pharmacokinetic (PK) and pharmacodynamics (PD) modeling [abstract]. Blood. 2002; 100: 9b., , .
- 17Amgen Inc. Aranesp® [package insert]. Thousand Oaks: Amgen Inc., 2002.